Welcome to our dedicated page for Kintara Therapeutics news (Ticker: KTRA), a resource for investors and traders seeking the latest updates and insights on Kintara Therapeutics stock.
Kintara Therapeutics, Inc. (Nasdaq: KTRA) generated frequent news as a biopharmaceutical company focused on developing new solid tumor cancer therapies and as the vehicle for a significant reverse merger with TuHURA Biosciences, Inc. Company press releases describe Kintara as located in San Diego, California and dedicated to novel cancer therapies for patients with unmet medical needs, with a lead program centered on REM-001 Therapy for cutaneous metastatic breast cancer (CMBC).
The KTRA news flow prominently features updates on REM-001 Therapy, including details of an open-label CMBC study, prior Phase 2/3 clinical experience, and the role of a Small Business Innovation Research grant from the National Institutes of Health in supporting study costs. These items provide context on the company’s proprietary late-stage photodynamic therapy platform, which combines a laser light source, a light delivery device, and the REM-001 drug product.
Another major theme in Kintara’s news coverage is its merger with TuHURA Biosciences, Inc. Articles outline the definitive merger agreement, stockholder meetings, voting instructions, and the strategic rationale for combining Kintara’s oncology assets with TuHURA’s Phase 3 registration-stage immuno-oncology programs. Releases discuss the expected ownership structure of the combined company, the planned corporate name change to TuHURA Biosciences, Inc., and the transition of trading to the Nasdaq Capital Market under the symbol HURA.
News items also detail corporate actions tied to the merger, including the approval and implementation of a 1-for-35 reverse stock split and the establishment of Contingent Value Rights (CVRs) to provide potential additional share consideration to Kintara stockholders upon achievement of specified REM-001 study milestones. Additional coverage includes reminders to stockholders to vote on key proposals, adjournments and reconvening of special meetings, and fiscal year financial results accompanied by corporate updates.
For readers following KTRA historically, this news archive offers insight into Kintara’s oncology development efforts, its financial and strategic decisions, and the sequence of events that led to the transformation of the Kintara listing into TuHURA Biosciences, Inc. under the HURA ticker. Regular review of these releases helps clarify how the company’s clinical programs and corporate structure evolved over time.
Kintara Therapeutics, Inc. (NASDAQ: KTRA) reported its fiscal second-quarter financial results for the period ending December 31, 2022. The company has cash reserves of approximately $4.9 million and experienced a net loss of about $3.5 million, a decrease from $5.9 million in the same period last year. Key developments include receiving FDA Orphan Drug Designation for VAL-083, which targets untreated childhood brain cancer, and Fast Track Designation for REM-001 therapy in metastatic breast cancer. Kintara paused the REM-001 program to preserve cash, expecting to save around $3 million in 2023. Upcoming data from the GBM AGILE Study is anticipated by year-end.
Kintara Therapeutics, a biopharmaceutical company focused on cancer therapies, will present at the BIO CEO & Investor Conference on February 6, 2023. CEO Robert E. Hoffman will discuss recent developments in their novel therapies, including updates on clinical trials and upcoming milestones. The presentation is scheduled for 4:30 p.m. EST at the Marriott Marquis in New York, NY.
Kintara is advancing its lead asset, VAL-083, in a Phase 2/3 trial for glioblastoma and is also developing REM-001 Therapy for cutaneous metastatic breast cancer. More information can be found at www.kintara.com.
Kintara Therapeutics (Nasdaq: KTRA), based in San Diego, is presenting at the Biotech Showcase Conference in San Francisco on January 10, 2023, at 11:30 am PST. CEO Robert E. Hoffman will discuss the company's innovative therapies for solid tumors, including VAL-083 and REM-001 Therapy, targeting unmet medical needs in cancer treatment. VAL-083 is in a registrational clinical trial for glioblastoma, while REM-001 has shown an 80% complete response in cutaneous metastatic breast cancer but is currently paused to conserve resources. More details are available on Kintara's website.
Kintara Therapeutics (KTRA) announced receiving Orphan Drug Designation (ODD) from the FDA for its drug VAL-083, aimed at treating diffuse intrinsic pontine glioma (DIPG), a rare childhood brain cancer. The ODD offers development incentives such as tax credits and seven-year marketing exclusivity upon FDA approval. Kintara's CEO, Robert E. Hoffman, emphasized the importance of this designation in advancing VAL-083 alongside their lead indication of glioblastoma. Kintara also has ongoing clinical programs for other cancer therapies, including REM-001 for cutaneous metastatic breast cancer.
Kintara Therapeutics, a biopharmaceutical firm, will have its President and CEO, Robert E. Hoffman, participate in the RHK Capital Disruptive Growth Conference in New York City on December 5, 2022, at 2:40 pm ET. The event will bring together executives and institutional investors to discuss growth-oriented companies. Kintara is developing innovative cancer therapies, including VAL-083 for glioblastoma and REM-001 for metastatic breast cancer. VAL-083 is currently in a registrational Phase 2/3 trial under the GBM AGILE Study.
Kintara Therapeutics, Inc. (KTRA) announced it has regained compliance with Nasdaq's minimum bid price requirement. A notice received on November 29, 2022, confirmed that KTRA's closing stock price exceeded $1.00 for 10 consecutive days. The company specializes in developing cancer therapies, with ongoing clinical trials for VAL-083 and REM-001 Therapy, targeting glioblastoma and cutaneous metastatic breast cancer respectively. Kintara has paused the REM-001 program to conserve cash, while VAL-083 is advancing through the GBM AGILE Study for regulatory support.
Kintara Therapeutics (KTRA) has received Fast Track Designation from the FDA for its REM-001 Therapy aimed at treating cutaneous metastatic breast cancer (CMBC). The therapy has shown an impressive 80% complete response rate in previous trials among patients who had received prior treatment. Kintara, which is currently seeking funding, plans to restart clinical studies to advance this therapy. The Fast Track Designation allows for enhanced FDA access and potential expedited review processes, which may accelerate product approval timelines.
Kintara Therapeutics (Nasdaq: KTRA) presented three posters at the 2022 Society for Neuro-Oncology Annual Meeting, held from November 16-20 in Tampa, Florida. Key highlights include:
- A Phase 2 study showing that two patients with newly-diagnosed GBM survived 53 and 35 months post-treatment with VAL-083.
- A case report on a patient with recurrent ependymoma who remains stable 18 months after treatment.
- Data from 14 recurrent GBM patients revealing no significant hematological adverse events with VAL-083.
Kintara aims to advance VAL-083 through the GBM AGILE study.
Kintara Therapeutics, Inc. (Nasdaq: KTRA) announced a 1-for-50 reverse stock split effective November 11, 2022, to meet Nasdaq's minimum bid price requirement of $1.00. The number of outstanding shares will decrease from approximately 80.8 million to about 1.6 million, with authorized shares reducing from 275 million to 5.5 million. This move aims to ensure continued trading on Nasdaq. The adjusted shares will begin trading on November 14, 2022. No stockholder approval was required, and fractional shares will be rounded up.
Kintara Therapeutics (Nasdaq: KTRA) reported its fiscal 2023 first quarter results, ending September 30, 2022. The company paused the REM-001 program to save approximately $3 million, redirecting funds to the VAL-083 registrational study in glioblastoma. Kintara's cash and equivalents totaled $7.1 million as of September 30, with a net loss of $4.6 million or $0.07 per share, improved from a $6 million loss in Q1 2022. The company has also entered a $20 million purchase agreement with Lincoln Park Capital, receiving $1.9 million to date.